• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Shared care plan: an extraordinary tool for the personalization of medicine and respect for self-determination.共同照护计划:医学个体化和尊重自主权的非凡工具。
Acta Biomed. 2020 Apr 29;92(1):e2021001. doi: 10.23750/abm.v92i1.9597.
2
Refusal of blood by Jehovah's Witnesses and the patient's right to self-determination.耶和华见证会成员拒绝输血与患者的自决权。
Leg Med (Tokyo). 2009 Apr;11 Suppl 1:S138-40. doi: 10.1016/j.legalmed.2009.02.005. Epub 2009 Mar 9.
3
In re Duran.关于杜兰案
Wests Atl Report. 2001;769:497-508.
4
Oncological management of pediatric cancer patients belonging to Jehovah's Witnesses: a two-institutional experience report.对属于耶和华见证人的小儿癌症患者的肿瘤学管理:一份双机构经验报告。
Onkologie. 2004 Apr;27(2):131-7. doi: 10.1159/000076901.
5
Blood transfusion and Jehovah's Witnesses: the legal and ethical issues.输血与耶和华见证会:法律和伦理问题。
Br J Nurs. 2005;14(5):270-4. doi: 10.12968/bjon.2005.14.5.17663.
6
Bioethics and religious bodies: refusal of blood transfusions in Germany.生命伦理学与宗教团体:德国的输血拒绝现象。
Soc Sci Med. 2013 Dec;98:271-7. doi: 10.1016/j.socscimed.2013.02.043. Epub 2013 Mar 14.
7
Meeting the clinical challenge of care for Jehovah's Witnesses.应对照顾耶和华见证人的临床挑战。
Transfus Med Rev. 2004 Apr;18(2):105-16. doi: 10.1016/j.tmrv.2003.12.004.
8
Justice and Respect for Autonomy: Jehovah's Witnesses and Kidney Transplant.公正与对自主性的尊重:耶和华见证人教徒与肾移植
J Clin Ethics. 2018 Winter;29(4):305-312.
9
Transfusion-free treatment of Jehovah's Witnesses: respecting the autonomous patient's rights.对耶和华见证人的无输血治疗:尊重自主患者的权利。
J Med Ethics. 1998 Oct;24(5):302-7. doi: 10.1136/jme.24.5.302.
10
Jehovah's Witnesses and blood transfusion: physicians' attitudes and legal precedents.耶和华见证人及输血问题:医生的态度与法律先例
South Med J. 1984 Apr;77(4):473-8. doi: 10.1097/00007611-198404000-00016.

引用本文的文献

1
Challenges of care coordination for complex patients among family medicine residents in a community ambulatory clinic: a qualitative study.家庭医学住院医师在社区门诊中为复杂患者进行护理协调的挑战:一项定性研究。
BMC Med Educ. 2024 May 23;24(1):562. doi: 10.1186/s12909-024-05543-7.
2
Italian law n. 219/2017 on consent and advance directives: survey among Ethics Committees on their involvement and possible role.意大利法律第 219/2017 号:关于同意和预先指示的法律:对伦理委员会参与和可能发挥的作用进行调查。
BMC Med Ethics. 2022 Nov 16;23(1):114. doi: 10.1186/s12910-022-00858-w.
3
Modifiers of and Disparities in Palliative and Supportive Care Timing and Utilization among Neurosurgical Patients with Malignant Central Nervous System Tumors.恶性中枢神经系统肿瘤神经外科患者姑息和支持治疗时机及利用情况的影响因素与差异
Cancers (Basel). 2022 May 23;14(10):2567. doi: 10.3390/cancers14102567.
4
Medication Errors in Pediatrics: Proposals to Improve the Quality and Safety of Care Through Clinical Risk Management.儿科用药错误:通过临床风险管理提高医疗质量和安全性的建议。
Front Med (Lausanne). 2022 Jan 14;8:814100. doi: 10.3389/fmed.2021.814100. eCollection 2021.
5
Health in Prison: Does Penitentiary Medicine in Italy Still Exist?监狱中的健康:意大利的监狱医学是否依然存在?
Healthcare (Basel). 2021 Nov 5;9(11):1511. doi: 10.3390/healthcare9111511.
6
Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT).一项随机对照试验的研究方案,旨在比较增强型知情同意与标准知情同意,以提高患者对早期肿瘤临床试验的理解(CONSENT)。
BMJ Open. 2021 Sep 6;11(9):e049217. doi: 10.1136/bmjopen-2021-049217.
7
The Motion of the Italian National Bioethics Committee on Aggressive Treatment towards Children with Limited Life Expectancy.意大利国家生物伦理委员会关于对预期寿命有限的儿童进行积极治疗的动议。
Healthcare (Basel). 2020 Nov 1;8(4):448. doi: 10.3390/healthcare8040448.

本文引用的文献

1
Rules on informed consent and advance directives at the end-of-life: the new Italian law.临终时的知情同意和预立医疗指示规则:意大利新法律
Clin Ter. 2020 Mar-Apr;171(2):e94-e96. doi: 10.7417/CT.2020.2195.
2
Patient Blood Management: a revolutionary approach to transfusion medicine.患者血液管理:输血医学的革命性方法。
Blood Transfus. 2019 May;17(3):191-195. doi: 10.2450/2019.0109-19.
3
Perspectives concerning the law on Advance Directives and Advance Care Planning and their effects on end-of-life care in Italian Intensive Care Units.关于预立医疗指示和预立照护计划的法律及其对意大利重症监护病房临终关怀影响的观点。
Minerva Anestesiol. 2019 Apr;85(4):338-341. doi: 10.23736/S0375-9393.19.13540-7.
4
A review and analysis of new Italian law 219/2017: 'provisions for informed consent and advance directives treatment'.意大利新法 219/2017 的回顾与分析:“知情同意和预先指示治疗的规定”。
BMC Med Ethics. 2019 Mar 4;20(1):17. doi: 10.1186/s12910-019-0353-2.
5
The contribution of legal medicine in clinical risk management.法医学在临床风险管理中的作用。
BMC Health Serv Res. 2019 Feb 1;19(1):85. doi: 10.1186/s12913-018-3846-7.
6
The Italian law on informed consent and advance directives: its impact on intensive care units and the European legal framework.意大利关于知情同意和预先指示的法律:对重症监护病房的影响和欧洲法律框架。
Minerva Anestesiol. 2019 Apr;85(4):401-411. doi: 10.23736/S0375-9393.18.13179-8. Epub 2018 Nov 21.
7
The Italian law on informed consent and advance directives: New rules of conduct for the autonomy of doctors and patients in end-of-life care.意大利关于知情同意和预先指示的法律:在临终关怀中规范医生和患者自主权的新行为准则。
J Crit Care. 2018 Dec;48:178-182. doi: 10.1016/j.jcrc.2018.08.039. Epub 2018 Aug 29.
8
[New italian law about end of life: self-determination and shared care pathway.].[关于生命终结的意大利新法律:自主决定权与共享照护路径。]
Recenti Prog Med. 2018 May;109(5):267-271. doi: 10.1701/2902.29245.
9
Law on advance health care directives: a medical perspective.《预先医疗照护指示法:医学视角》
Clin Ter. 2018 Mar-Apr;169(2):e77-e81. doi: 10.7417/T.2018.2058.
10
The Italian Regulatory Guidelines for the implementation of Patient Blood Management.意大利患者血液管理实施监管指南。
Blood Transfus. 2017 Jul;15(4):325-328. doi: 10.2450/2017.0060-17. Epub 2017 May 3.

共同照护计划:医学个体化和尊重自主权的非凡工具。

Shared care plan: an extraordinary tool for the personalization of medicine and respect for self-determination.

机构信息

Array.

Department of Molecular Medicine, Legal Medicine, University of Padua, Padua, Italy.

出版信息

Acta Biomed. 2020 Apr 29;92(1):e2021001. doi: 10.23750/abm.v92i1.9597.

DOI:10.23750/abm.v92i1.9597
PMID:33682824
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7975960/
Abstract

BACKGROUND

On 22 December 2017, Law No. 219 was approved in Italy. This law provides citizens with effective tools with which to express healthcare decisions: namely, advance treatment directives (ATD) and shared care plans (SCP).

METHODS

This article presents an analysis of 70 SCP cases carried out in a tertiary hospital in Italy during the period between 01.02.2018 and 29.02.2020 inclusive.

RESULTS

In 90% of cases, the objective of the plan pertained to situations regarding patients' refusal of transfusions of blood components, the majority (97%) due to their belonging to the religious movement of Jehovah's Witnesses. 46% of the sample had drafted ATDs. The course of treatment recommended by the attending physicians was confirmed in 93% of the SCP cases. Trustees were appointed in 96% of cases. In 55% of cases, patients assigned trustees with attestative functions and the remaining 45% with creative functions. The results demonstrate that each patient personally dictates his or her wishes and the role assigned to the trustee. SCP meetings serve as a useful tool for providing the patient and his or her relatives with information, and for appointing a trustee. However, it has never been necessary to solicit the intervention of the trustee following a surgical operation.

CONCLUSIONS

The SCP has proven to be an essential tool in achieving the objective of personalised medicine. However, there is still notable passivity in its application. Further effort is required in order for it to become a common asset in clinical practice.

摘要

背景

2017 年 12 月 22 日,意大利通过了第 219 号法案。该法案为公民提供了表达医疗决策的有效工具:即预先治疗指令(ATD)和共同护理计划(SCP)。

方法

本文分析了意大利一家三级医院在 2018 年 2 月 1 日至 2020 年 2 月 29 日期间进行的 70 例 SCP 案例。

结果

在 90%的情况下,计划的目标涉及患者拒绝输血的情况,其中大多数(97%)是因为他们属于耶和华见证人的宗教运动。46%的样本起草了 ATD。主治医生推荐的治疗方案在 93%的 SCP 病例中得到了确认。在 96%的情况下任命了受托人。在 55%的情况下,患者指定了具有证明职能的受托人,其余 45%具有创造性职能的受托人。结果表明,每位患者都亲自决定自己的意愿和受托人的角色。SCP 会议是向患者及其家属提供信息和任命受托人的有用工具。然而,在进行手术操作后,从未有必要请求受托人进行干预。

结论

SCP 已被证明是实现个性化医疗目标的重要工具。然而,在其应用方面仍然存在明显的被动性。需要进一步努力,使其成为临床实践中的共同资产。